Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1775)	8/28/2007 4:28:16 PM
From: tuck	Read Replies (1) \| Respond to of 1826

[A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis] Full-text freebie. bloodjournal.hematologylibrary.org Can't find anything on AKR-501 in pubmed, but the above may serve as an intro to the concept of c-Mpl agonism. Unclear to me if Nissan is still developing NIP-004. It is clearly well behind AKR-501, however, and I don't see anything else going after this target. There are other compounds against the disease in development, such as Ligand's TPO mimic partnered with GSK, also in P2. Cheers, Tuck